Kaustubh Ajit Kolekar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kaustubh Ajit Kolekar has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Sachin Kumar Singh
School of Pharmaceutical Sciences Lovely Professional University Phagwara Punjab India
6 shared publications - John Disouza
Department of Pharmaceutics, Bombay Institute of Pharmacy and Research, Dombivali (East), Dist. Thane, India
5 shared publications Bushra Bashir
4 shared publications- Popat S. Kumbhar
Department of Pharmaceutics, Tatyasaheb Kore College of Pharmacy, Warananagar, Tal: Panhala, Dist: Kolhapur, Maharashtra, 416113, India
4 shared publications Gaurav Gupta
3 shared publications- Amarjitsing Rajput
Department of Pharmaceutics, Poona College of Pharmacy, Bharti Vidyapeeth (Deemed to be University), Pune, India
2 shared publications
Latest Publications
- 10 November 2026
- Published by Elsevier in Drug Discovery Today
- Vol. 31 (6)
Harnessing exosomes for breast cancer: bridging conceptual promise to tangible translational application
- 10 November 2026
- Published by Elsevier in Drug Discovery Today
- Vol. 31 (6)
Harnessing exosomes for breast cancer: bridging conceptual promise to tangible translational application
- 29 September 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (9) , e70347
Target‐Based Antitubercular Drug Discovery: Scaffold Diversity and SAR Trends of Small Molecules Against Mycobacterium Tuberculosis
Tuberculosis remains a major infectious disease, and the increasing incidence of multidrug‐resistant Mycobacterium tuberculosis continues to limit current treatment options. This review summarizes recent medicinal chemistry efforts directed toward six important M. tuberculosis targets: InhA, DprE1, MmpL3, QcrB, DNA gyrase, and dihydrofolate reductase (DHFR). Emphasis is placed on the structural diversity and biological activity of potent molecules. SAR analysis relates changes in scaffold, substituent pattern, linker geometry, lipophilicity, and polarity to antimycobacterial potency and activity against resistant strains. Selected synthetic routes and clinically relevant antitubercular compounds are also discussed. Selected docking studies provide supportive structural information for representative potent inhibitors, while comparative SAR analysis provides an overview of the major structural features associated with activity across the target classes. Overall, the review summarizes recent medicinal chemistry advances in targeted antitubercular drug discovery and provides SAR considerations for further lead optimization.
- 29 September 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (9) , e70347
Target‐Based Antitubercular Drug Discovery: Scaffold Diversity and SAR Trends of Small Molecules Against Mycobacterium Tuberculosis
Tuberculosis remains a major infectious disease, and the increasing incidence of multidrug‐resistant Mycobacterium tuberculosis continues to limit current treatment options. This review summarizes recent medicinal chemistry efforts directed toward six important M. tuberculosis targets: InhA, DprE1, MmpL3, QcrB, DNA gyrase, and dihydrofolate reductase (DHFR). Emphasis is placed on the structural diversity and biological activity of potent molecules. SAR analysis relates changes in scaffold, substituent pattern, linker geometry, lipophilicity, and polarity to antimycobacterial potency and activity against resistant strains. Selected synthetic routes and clinically relevant antitubercular compounds are also discussed. Selected docking studies provide supportive structural information for representative potent inhibitors, while comparative SAR analysis provides an overview of the major structural features associated with activity across the target classes. Overall, the review summarizes recent medicinal chemistry advances in targeted antitubercular drug discovery and provides SAR considerations for further lead optimization.
- Open Access
- 7 September 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (37) , e71672
Opening Avenues for Rheumatoid Arthritis Treatment via Transdermal Application of Microneedles: Progress so far and Future Outlook
Rheumatoid arthritis (RA) is a chronic autoimmune disease with a global prevalence of 0.5% to 2%, causing serious impairment and early mortality. Presently approved therapeutics comprising non‐steroidal anti‐inflammatory drugs (NSAIDs), disease‐modifying anti‐rheumatic drugs (DMARDs), corticosteroids, etc. only lower pain, edema, and inflammation. Most of these therapeutics have been administered orally, intravenously, and intra‐articularly, minimizing patient adherence. Additionally, high doses of these drugs need to be taken for a long duration and have poor specificity, causing fatal side effects. The conventional and nanocarrier (NCs)‐based topical cargo delivery pose challenges like poor residence, possibility of skin reactions, and low patient adherence. Therefore, transdermal delivery of these therapeutics using microneedles (MNs) can be promising to improve permeability, bioavailability, targeting, and patient compliance while minimizing side effects. Moreover, NCs‐assisted MNs, biomimetic NCs‐based MNs, and MNs for biologics delivery have also emerged as a promising platform for targeting RA efficiently. This review attempts to give an overview on the transdermal drug delivery using MNs and NCs‐based MNs in the efficient management of RA. Thus, different MNs and their amalgamation with NCs could effectively deliver and manage RA via the transdermal route.
- 7 September 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (37) , e71672
Open AccessOpening Avenues for Rheumatoid Arthritis Treatment via Transdermal Application of Microneedles: Progress so far and Future Outlook
Rheumatoid arthritis (RA) is a chronic autoimmune disease with a global prevalence of 0.5% to 2%, causing serious impairment and early mortality. Presently approved therapeutics comprising non‐steroidal anti‐inflammatory drugs (NSAIDs), disease‐modifying anti‐rheumatic drugs (DMARDs), corticosteroids, etc. only lower pain, edema, and inflammation. Most of these therapeutics have been administered orally, intravenously, and intra‐articularly, minimizing patient adherence. Additionally, high doses of these drugs need to be taken for a long duration and have poor specificity, causing fatal side effects. The conventional and nanocarrier (NCs)‐based topical cargo delivery pose challenges like poor residence, possibility of skin reactions, and low patient adherence. Therefore, transdermal delivery of these therapeutics using microneedles (MNs) can be promising to improve permeability, bioavailability, targeting, and patient compliance while minimizing side effects. Moreover, NCs‐assisted MNs, biomimetic NCs‐based MNs, and MNs for biologics delivery have also emerged as a promising platform for targeting RA efficiently. This review attempts to give an overview on the transdermal drug delivery using MNs and NCs‐based MNs in the efficient management of RA. Thus, different MNs and their amalgamation with NCs could effectively deliver and manage RA via the transdermal route.
- 13 September 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 114
Wound healing management using microneedle array patch: Journey so far and road ahead
- 13 September 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 114
Wound healing management using microneedle array patch: Journey so far and road ahead
- 1 September 2024
- Published by Springer Nature
- p. 117-134
Future of Trends in the Design and Development of PROTAC
- 1 September 2024
- Published by Springer Nature
- p. 117-134
Future of Trends in the Design and Development of PROTAC